Social Determinants of Health and their Impact on COVID-19

Immunological and Autoimmune Disorders

Merck to Acquire Harpoon Therapeutics; Novo Nor...

Lutikizumab Showed Positive Results in a Phase II Trial of Adults with Moderate to Severe Hidradenitis Suppurativa as Program Advances to Phase III AbbVie has reported the results of Phase II trial...

Jan 09, 2024

Pharma News for Eisai, Biogen, Merck, BMS, Kyverna
Eisai Submits Marketing Authorization Application for Tasurgratinib; CHMP Issues Positive Opinion for Biogen’s SKYCLARYS; European Commission Approves Merck’s KEYTRUDA + Chemotherapy HER2-ve Gastric or GEJ Adenocarcinoma; BMS Provides Update on RELATIVITY-123 Trial; Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101; Verrica and Torii Pharma Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208

Eisai Submits Marketing Authorization Application In Japan for Anticancer Agent Tasurgratinib For Biliary Tract Cancer With FGFR2 Gene Fusion Eisai Co., Ltd. has officially submitted a request for marketing authorization in Japan for tasurgratinib succinate, its internally developed tyrosine kinase inhibitor tar...

Find More
Implantable Drug Delivery Devices Market Outlook
Assessing the Emerging Trends in the Evolving Implantable Drug Delivery Device Landscape

The Implantable Drug Delivery Device market has experienced a monumental surge driven by an amalgamation of technological innovation, burgeoning demand, and the strategic maneuvers of key industry players. According to DelveInsight's latest assessment, the global Implantable Drug Delivery Device Market is poised to...

Find More
stelara-biosimilar-wezlana
Could Amgen’s Biosimilar Wezlana Pose a Challenge to Johnson & Johnson’s Stelara

The FDA recently approved Amgen’s Wezlana (ustekinumab-auub) for various inflammatory conditions, marking the first biosimilar approval referencing the popular J&J drug Stelara (ustekinumab). Wezlana, mirroring its reference product, is approved for treating multiple inflammatory diseases in adults, including m...

Find More

More Views & Analysis

Pharma News for Sanofi, Sosei, AstraZeneca, Arcturus
Dupixent Significantly Reduced COPD Exacerbations; Sosei Heptares to Regain Ownership of GSK4381406; AstraZeneca Gains Rights to Usynova’s KRAS Inhibitor; FDA Approvs OGSIVEO for Desmoid Tumors; Orphan Drug Designation for ARCT-032 for the Cystic Fibrosis; FDA Fast Track Designation for ADP101 for Food Allergies

Dupixent Significantly Reduced COPD Exacerbations In Second Positive Phase III Trial The latest trial for Dupixent (dupilumab) in chronic obstructive pulmonary disease (COPD), called NOTUS, has delivered promising results. It showed a significant 34% reduction in COPD exacerbations, confirming earlier positive f...

Find More

Pharma News for Takeda, AskBio, Bayer, Lipella
Takeda’s ADZYNMA Approved by FDA; AskBio Presents Preliminary Data from Phase I Trial of Gene Therapy for CHF; Bayer’s Aflibercept 8 mg Recommended for Approval in EU; FDA Orphan Drug Designation to MAIA Biotechnology’s THIO; First Patient Dosed in Phase III ProstACT GLOBAL Study; FDA Grants Orphan Designation for Lipella’s LP-310 Drug Candidate

Takeda’s ADZYNMA Approved by FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura Takeda has received FDA approval for ADZYNMA (ADAMTS13, recombinant-krhn) for both prophylactic and on-demand treatment in adults and pediatri...

Find More

Pharma News for Pfizer, UCB, BioMarin
FDA Approves PENBRAYA for Most Common Serogroups Causing Meningococcal Disease; BIMZELX Approved Moderate to Severe Plaque Psoriasis; FDA Approves BioMarin’s VOXZOGO; FDA Fast Track Designation to ANPD001 for Parkinson’s Disease; UCB Announces FDA Approval of ZILBRYSQ; EMA Granted Orphan Drug Designation to Lisata’s LSTA1

UCB announces FDA approval of ZILBRYSQ for the Treatment of Adults with Generalized Myasthenia Gravis On the 17th of October 2023, UCB (Euronext Brussels: UCB) made an announcement regarding the approval of ZILBRYSQ® (zilucoplan) by the US FDA for the management of generalized myasthenia gravis (gMG) in adult pa...

Find More

Allergy Diagnostics Market Trends
Allergy Diagnostics: Unraveling the Science, Market Trends, and Future Prospects

Allergies are on the rise globally, affecting millions of people and significantly impacting their quality of life. The ability to accurately diagnose and manage allergies is crucial for both patients and healthcare providers. With the rising prevalence of allergy, the demand for Allergy Diagnostics has increased m...

Find More

Immunomodulators Market and Key Applications
Harnessing the Power of Immunomodulators: Applications and Implications

The human immune system has a magnificent defense system that works continuously to protect the body from numerous infections and outside invaders. Maintaining a healthy immune response through the intricate interplay of cells, chemicals, and signaling pathways is essential for general health and well-being. Immuno...

Find More

Pharma News for Amgen, Anaptys, Sanofi, Boehringer
Amgen to Acquire Horizon Therapeutics; Sanofi and Teva Announce Collaboration; Boehringer Obesity Drug Trial Update; FDA Places Partial Clinical Hold on IND for Lacutamab in CTCL/PTCL; Anaptys Announces Phase 3 Clinical Trial Results of Imsidolimab; Orphan Drug Designation to GC Biopharma’s GC1126A

Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment Sanofi and Teva Pharmaceuticals, a subsidiary of Teva Pharmaceutical Industries Ltd. in the United States, have announced a collaboration to co-develop and co-commercialize asset TEV'574, which is currently in Phase ...

Find More

The convergence of technologies and the increasing integration of medical devices to computer networ.....

Find More

Uremic Pruritusis also known as chronic kidney disease-associated pruritus (CKD-aP), is a chronic it.....

Find More

Over the years, the Oncology domain has experienced the entry of several treatment approaches. Thera.....

Find More

Doctors and scientists have recognized that traditional, complementary and alternative therapies hav.....

Find More

Acromegaly is a rare, slowly progressive disorder that is caused when the pituitary glands produce t.....

Find More

Retinitis pigmentosa is a gradual deterioration of the ability of eyes to see. The defect in the eye.....

Find More